<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594579</url>
  </required_header>
  <id_info>
    <org_study_id>075802</org_study_id>
    <nct_id>NCT02594579</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D3 Supplementation on Muscle Mass in ICU Patient</brief_title>
  <official_title>Effect of High Dose Vitamin D3 Supplementation on Skeletal Muscle Mass and Body Compositions in Critically Ill Patients With Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double blind placebo control trial study will be conducted in critically ill
      patients with vitamin D deficiency. Investigator aimed to study the effect of oral vitamin D3
      supplementation, compare to placebo, on skeletal muscle mass and body composition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a high prevalence of vitamin D deficiency in critically ill patient which is
      associated with muscle wasting and physical disability. Recent study showed that treatment of
      vitamin D deficiency with high dose vitamin D improved muscle wasting and may prevent further
      muscle breakdown.

      Investigator want to explore whether a high dose vitamin D3 supplementation, compare to
      placebo will be able to improve muscle wasting in critically ill patients.

      The eligible participant will be asked to sign and date the informed consent document then
      they will be randomized to receive vitamin D3 supplement or placebo, using the computer
      generated code in conceal envelope.

      Vitamin D3 or placebo will be given orally or feeding tube via feeding tube at a dose of
      100,000 IU on day 1 and 3 then 50,000 IU on day 5,7,9,12 followed by 150,000 unit per week
      for 4 week.

      Serum 25-Hydroxyvitamin D, 1,25-dihydroxyvitamin D will be measured at baseline (day 0) then
      day 10 and day 43 after vitamin D supplementation. Moreover, Investigator will assess the
      diameter of rectus femoris by using ultrasonography on day 0,10 and 43.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rectus femoris cross-sectional diameer</measure>
    <time_frame>Change from baseline Rectus femoris cross-sectional diameter at day 43</time_frame>
    <description>A difference of change from baseline Rectus femoris cross-sectional diameter at day 43 in participant who receive cholecalciferol or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stays</measure>
    <time_frame>An expected average of 3 weeks</time_frame>
    <description>Participant will be followed for the duration of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stays</measure>
    <time_frame>An expected average of 2 weeks</time_frame>
    <description>Participant will be followed for the duration of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of skeletal muscle mass</measure>
    <time_frame>Change from basline percentage skeletal muscle mass at day 43</time_frame>
    <description>Percentage of skeletal muscle mass will be assessed using bioelectrical impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correction vitamin D deficiency</measure>
    <time_frame>43 days</time_frame>
    <description>Number percentage of participant who above 25(OH)D concentration above or equal 30 in participant who receive cholecalciferol or placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Sarcopenia</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol (D3-50)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cholecalciferol (D3-50) placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 70 years old

          -  Expected ICU stay â‰¥ 48 hrs

        Exclusion Criteria:

          -  Participate in other clinical trial

          -  Contraindication to receive oral or enteral feeding

          -  Do not resuscitate /imminent death

          -  Vegetative state, generalize weakness, denervation of leg, both leg amputation

          -  Hypercalcemia or Hypercalcemia at risk

          -  Hyperphosphatemia,

          -  History of nephrolithiasis

          -  End stage renal disease on renal replacement therapy

          -  Pregnancy/lactation

          -  Consent refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daruneewan Warodomwichit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nutrition and Biochemical medicine, Department of Medicine, Faculty of medicine, Ramathibodi Hospital, Mahidol University Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daruneewan Warodomwichit</last_name>
    <phone>(662)2011000</phone>
    <phone_ext>0082</phone_ext>
    <email>daruneewan@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine, Faculty of medicine, Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daruneewan Warodomwichit</last_name>
    </contact>
    <investigator>
      <last_name>Daruneewan Warodomwichit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Praopilad Srisuwarn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

